Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit.

Following the Q1 loss and guidance update, the stock has been volatile, with a 1 day share price return of 3.34%, a year to date share price decline of 25.02%, and a 3 year total shareholder return of 156.40% that highlights how sentiment has swung over time.

If this kind of sharp move has your attention, it can be worth widening your watchlist to see which other telehealth and medical platforms are gaining traction in AI enabled care, starting with 32 healthcare AI stocks.

So with Hims & Hers guiding to higher 2026 sales but accepting weaker margins and a Q1 loss, is the recent share price slide giving you a mispriced growth story, or is the market already factoring in those ambitions?

Most Popular Narrative: 70.9% Undervalued

Compared with Hims & Hers Health's last close at $25.05, the most followed narrative points to a fair value of $86.09, a wide gap that has investors asking what assumptions sit underneath that view.

Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock. It is quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco: deliver more value per dollar spent, reinvest scale advantages, and aim to win via customer-centric efficiency.

The narrative leans heavily on rapid subscriber gains, rising monetisation per user, and a generous future profit multiple included in that $86.09 fair value. This raises questions about which growth and margin assumptions would need to hold for that valuation to be supported.

Result: Fair Value of $86.09 (UNDERVALUED)

However, this hinges on regulation and partner relationships. Tighter GLP-1 scrutiny or further fallout, such as the Novo Nordisk cancellation, could quickly challenge that optimistic setup.

Another Angle On Valuation

There is a twist when you look at Hims & Hers using its P/S ratio instead of the narrative fair value. The stock trades on 2.4x sales, which is expensive versus the US Healthcare industry at 1.2x, but below peers at 4.1x and a fair ratio of 4.9x that the market could move toward. That mix of premium and discount raises the question of whether the risk sits more in expectations or in missing a potential rerating.

Next Steps

With sentiment this divided, it makes sense to look at the full picture yourself and decide quickly where you stand on Hims & Hers. You can start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Hims & Hers is already on your radar, now is the moment to broaden your search and line up the next set of watchlist candidates.

• Target potential bargains by checking out quality companies trading at attractive valuations with 51 high quality undervalued stocks.
• Prioritise resilience by scanning for companies that score well on financial strength using the solid balance sheet and fundamentals stocks screener (45 results).
• Spot early opportunities that others may be overlooking with the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.